Abreu, J+Legal, CS advise on purchase and sale of GenIbet

Abreu Advogados, J+Legal and CS’Associados have advised on the purchase and sale of the biopharmaceutical GenIbet

pjimage 2022 02 14T110703.711Abreu Advogados, J+ Legal and CS’Associados have advised on the purchase and sale of the Portuguese biopharmaceutical company GenIbet. This is now the latest acquisition of the multinational Recipharm, in a landmark operation of the first quarter of the year in the Portuguese Pharmaceutical and Life Sciences sectors.

GenIbet is a Portuguese biopharmaceutical company recognized for its work in the development of biological medicines, specializing in the manufacture of biological clinical trial material and novel modalities such as viral vectors, messenger RNA and microbiome.

Recipharm is a Swedish multinational company dedicated to the development and production of medicines for the pharmaceutical industry, employing almost 9,000 employees, that will now expand its reach and operation with the acquisition of GenIbet.

Abreu Advogados advised the multinational pharmaceutical company Recipharm AB on this cross border operation, with a multidisciplinary team led by the professional partner José Carlos Vasconcelos (pictured left), which also included the lawyers Inês Sequeira Mendes, partner, Ana Manuela Barbosa, associated partner, Ricardo Henriques, partner, and Mafalda Teixeira de Abreu, professional partner.

On the selling side, J+ Legal advised the sellers IBET, Medinfar, Nutrinveste and Pentafar. The team was coordinated by Jorge Brito Pereira (pictured centre), partner, and Rui Bello da Silva, senior associate. IBET was also advised on this operation by CS Associados and a team coordinated by partner Maria Castelos (pictured right) and counsel Ofélia Pinto de Queiroz.

Michael Heron